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Abstract
Circulating levels of adiponectin, a hormone produced predominantly by adipocytes, are highly heritable and are inversely
associated with type 2 diabetes mellitus (T2D) and other metabolic traits. We conducted a meta-analysis of genome-wide
association studies in 39,883 individuals of European ancestry to identify genes associated with metabolic disease. We
identified 8 novel loci associated with adiponectin levels and confirmed 2 previously reported loci (P=4.5 610
28–
1.2610
243). Using a novel method to combine data across ethnicities (N=4,232 African Americans, N=1,776 Asians, and
N=29,347 Europeans), we identified two additional novel loci. Expression analyses of 436 human adipocyte samples
revealed that mRNA levels of 18 genes at candidate regions were associated with adiponectin concentrations after
accounting for multiple testing (p,3610
24). We next developed a multi-SNP genotypic risk score to test the association
of adiponectin decreasing risk alleles on metabolic traits and diseases using consortia-level meta-analytic data. This risk
score was associated with increased risk of T2D (p=4.3 610
23, n=22,044), increased triglycerides (p=2.6 610
214,
n=93,440), increased waist-to-hip ratio (p=1.8 610
25, n=77,167), increased glucose two hours post oral glucose
tolerance testing (p=4.4 610
23, n=15,234), increased fasting insulin (p=0.015, n=48,238), but with lower in HDL-
cholesterol concentrations (p=4.5 610
213, n=96,748) and decreased BMI (p=1.4 610
24, n=121,335). These findings
identify novel genetic determinants of adiponectin levels, which, taken together, influence risk of T2D and markers of
insulin resistance.
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Introduction
Adiponectin is a highly abundant adipocyte-derived plasma
protein whose levels correlate inversely with a range of important
clinical parameters including blood glucose, indices of insulin
resistance, proatherogenic dyslipidemia, and risk of type 2 diabetes
(T2D), stroke and coronary artery disease [1,2,3,4]. Collectively
these conditions account for most of the burgeoning pandemic of
Adiponectin: Multiethnic Genome-Wide Meta-Analysis
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global healthcare challenge [5]. Murine studies suggest that
adiponectin plays a mediating role in at least some of these obesity-
related complications, and although less clearly established in
humans, this suggests that understanding the pathophysiology of
adiponectin may uncover novel therapeutic targets in major,
highly prevalent human disease.[6,7].
Twins and family studies have revealed moderate to high
estimates of heritability (30–70%) for plasma adiponectin levels
[8,9,10,11]. However, until recently, few genes associated with
adiponectin levels have been identified. Candidate and genome-
wide association studies (GWAS) have shown pronounced
associations between common polymorphisms in the adiponectin
gene (ADIPOQ) and adiponectin levels [12,13,14,15]. A recent
meta-analysis of three GWAS for adiponectin levels identified
variants in a novel candidate gene, ARL15, that were associated
with adiponectin levels, coronary heart disease (CHD), T2D and
other metabolic traits [16]. Furthermore, CDH13 and KNG1 genes
were found to be associated with adiponectin levels in two studies
involving East Asian populations [17,18]. Although part of the
variance explained by the ADIPOQ locus, most of the heritability of
adiponectin levels remains unaccounted for. Therefore, we sought
to identify novel common variants influencing adiponectin levels
and test their association with risk of T2D and related metabolic
traits within the framework of a large multi-ethnic consortium of
GWAS.
We combined genome-wide association results of 35,355
individuals from three different ethnicities (white Europeans
(n=29,347), African American s(n=4,232) and East Asians
(n=1,776)), applying a novel meta-analytic method to allow for
heterogeneity in allelic effects between populations of different
ethnic backgrounds. We next examined whether identified
genome-wide significant single nucleotide polymorphisms (SNPs)
also associated with expression of their nearest gene in human
adipocytes, the main source of adiponectin. Since adiponectin has
been associated with T2D, insulin resistance and metabolic traits
we next investigated whether a multi-SNP genotypic risk,
comprising genome-wide significant SNPs for adiponectin levels,
also influenced risk of T2D and related traits measured in the
DIAbetes Genetics Replication and Meta-analysis (DIAGRAM+)
[19], Meta-Analysis of Glucose and Insulin Related Traits
Consortium (MAGIC) [20], Genetic Investigation of ANthropo-
metric measures Traits (GIANT) [21] , Global Lipids Genetic
Consortium (GLGC) [22], and Body Fat GWAS consortia [23].
Results
Results of Meta-Analysis of GWAS
The meta-analysis was divided into four phases 1) Discovery
phase, which involved cohorts providing GWAS results, 2) In-
silico replication phase which included additional GWAS cohorts
joining our meta-analysis after the completion of the discovery
phase, 3) De-novo genotyping in cohorts without GWAS
genotyping and 4) Multi-Ethnic meta-analysis applying a novel
method for complex trait mapping using different ethnicities.
Discovery phase in individuals of white European
origin. The meta-analysis of sex-combined data from 16
GWAS (n=29,347) of individuals of white European descent
identified ten loci associated with adiponectin levels at p#5.0610
28
(Table 1 and Figure 1A and Figure S1, Table S2). These results
include the previously described associations with adiponectin at
ADIPOQ (rs6810075[T]; ß=0.06, p-value=3.60610
241), KNG1
(rs2062632[T]; ß=0.05, p-value=2.52610
219) on 3q27.3, and
CDH13 (rs12922394[T; ß=20.1, p=3.16610
218) on 16q23.3
(Table 1). Furthermore, we identified variants that showed genome-
wide significant association in eight novel independent loci
including rs9853056 (within the STAB1 gene, rs4282054 (within
the NT5DC2 gene), rs13083798 (within the PBRM1 gene), rs1108842
(within the GNL3 gene), rs11235 (within the NEK4 gene), rs2710323
(within the ITIH1 gene), rs3617 (within the ITIH3 gene), and
rs2535627 (within 200 Kb of ITIH4 gene) at 3p21.1; rs1597466
(within 1 Mb of TSC22D2 gene) at 3q25.1; rs2980879 (within 1 Mb
of TRIB1 gene) at 8q24.13; rs7955516 (within 1.3 Mb PDE3A gene)
at 12p12.2; rs601339 (within the GPR109A gene) at 12q24.31;
rs6488898 (within the ATP6V0A2 gene), rs7133378 (within the
DNAH10 gene), rs7305864 (within the CCDC92 gene), and
rs7978610 (within the ZNF664 gene at 12q24.31, which is 1.3 Mb
away from GPR109A); rs2925979 (within the CMIP at 16q23.2
gene);andrs731839(withinthePEPDgene)at19q13.11.(Figure2A–
2E, Table 1).
In our analysis a common variant (rs601339, MAF=0.18, allele
G) downstream of the GPR109A gene (the putative niacin receptor)
was associated with adiponectin (ß=0.04, p=7.94610
210)a n d
HDL-C (ß=0.03, p=5.59610
27) in the global lipid analysis. In a
coincident candidate gene analysis 11 SNPs were typed in
GPR109A/B in CoLaus and LOLIPOP cohorts, containing
individuals of European descent. A single nominally significant
coding SNP R311C (rs7314976, MAF=0.14) within the GPR109A
gene was taken forward for replication and found to be consistently
associated with adiponectin in the three cohorts (CoLaus, Fenland
and MRCEly study,n=8285,p=4.6610
28) and HDL-cholesterol
(HDL-C) in four cohorts (CoLaus, Fenland, Ely study and Lolipop,
n=18425, p=2.9610
28) (Figure S2A, S2B). However R311C and
rs601339 were not in linkage disequilibirium with each other
(r2=0.04). Therefore the two variants represent two independent
signals from the same locus but with similar effects on HDL-
cholesterol and adiponectin.
In silico follow-up phase. In the in-silico follow-up phase
468 SNPs demonstrating genome-wide significant (p,5610
28 )o r
suggestive (p,5610
26) association with adiponectin in the
discovery phase were tested for association in additional
European cohorts. (Table S3). These SNPs were tested in seven
additional GWAS datasets (n=6,623 from NHS, HPFS, HABC,
ERF2, LLS, GARP and ARIC studies) and the combined meta-
Author Summary
Serum adiponectin levels are highly heritable and are
inversely correlated with the risk of type 2 diabetes (T2D),
coronary artery disease, stroke, and several metabolic
traits. To identify common genetic variants associated with
adiponectin levels and risk of T2D and metabolic traits, we
conducted a meta-analysis of genome-wide association
studies of 45,891 multi-ethnic individuals. In addition to
confirming that variants at the ADIPOQ and CDH13 loci
influence adiponectin levels, our analyses revealed that 10
new loci also affecting circulating adiponectin levels. We
demonstrated that expression levels of several genes in
these candidate regions are associated with serum
adiponectin levels. Using a powerful novel method to
assess the contribution of the identified variants with other
traits using summary-level results from large-scale GWAS
consortia, we provide evidence that the risk alleles for
adiponectin are associated with deleterious changes in
T2D risk and metabolic syndrome traits (triglycerides, HDL,
post-prandial glucose, insulin, and waist-to-hip ratio),
demonstrating that the identified loci, taken together,
impact upon metabolic disease.
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detected additional loci on chromosomes 1q41 near the LYPLAL1
gene (rs3001032, p=3.6610
28) and chromosome 6p21.1 near the
VEGFA gene (rs998584, p=5.8610
212) that reached genome-wide
significance. While we confirmed seven loci that had reached
genome-wide significance at the discovery stage (Table 1, Figure 2F
and 2G, Table S2), two identified loci (3q25.1 and 12q24.31) did
not remain genome-wide significant in the joint analysis of
discovery and follow-up results.
De novo follow-up phase. Next, in the de-novo genotyping
follow-up phase, we genotyped 10 SNPs with suggestive evidence
of association (5610
28,p,5610
26) from the meta-analysis of the
discovery and in-silico follow-up phases in an additional 3,913
individuals. Meta-analyzing the discovery and 2 follow-up stages
identified a SNP in ARL15 (rs6450176 [G]; ß=0.026,
p=5.8610
28), which was initially described in a previous
GWAS for adiponectin levels (Table S3) [16].
Multi-ethnic meta-analysis. To identify loci influencing
adiponectin levels in non-European individuals we performed an
additional analysis in 4,232 individuals from an African American
population and 1,776 individuals from an East Asian population.
In the African American populations, only associations at the
ADIPOQ locus reached genome-wide significance, while in the
East Asian population there was evidence of association at the
ADIPOQ and CDH13 loci (Table S4). Subsequently, we performed
a meta-analysis that combined all available GWAS including those
of white European origin, African American and East Asian
ancestry using novel method MANTRA [24]. This analysis
identified two additional loci in or near IRS1 gene on 2q36.3 and
at 6q24.1 within a gene desert. (Table 2, Figure 1B).
Secondary GWAS analyses. We next performed meta-
analysis of the GWAS data in women (n=16,685) and men
(n=12,662) separately (Figure S2A, S2B, Tables S5 and S6).
Although no novel loci reached genome-wide significance in
women or men separately, three loci (chromosome 3p, 8 and 12)
associated with adiponectin levels in the sex-combined analysis
showed evidence of association (p value,561028) in women
(Figure S3). Since different assays were used to measure
adiponectin levels, we next tested whether stratification by assay
rendered similar results and found the results were highly
concordant with the combined analysis. GWAS for high
molecular weight adiponectin in the CHS study (n=2,718)
identified 2 SNPs in ADIPOQ (rs17300539, p=3.0610
216) and
CMIP (rs2927307, p=2.7610
28). These two genes are located
within the loci identified in our discovery meta-analysis of
adiponectin levels.
Gene Expression Studies
Through gene expression studies we sought to address two
questions: First, are any of the SNPs that were genome-wide
significant for adiponectin levels associated with expression of their
nearest transcripts (cis-eQTLs) and second, whether mRNA levels
of loci identified through the GWAS for adiponectin levels are
associated with circulating adiponectin levels. To address the first
question, we examined whether SNPs within 1 Mb of the SNPs
achieving genome-wide significance in the discovery stage were
associated with the expression levels of nearby genes in human
adipocytes from 776 participants of the MuTHER Consortium
[25]. We identified 74 SNPs in three eQTLs to be associated with
the expression of five genes in adipocytes, using an array-wide level
of statistical significance for eQTLs (P,5.1610
25. See Materials
and Methods for details). These genes included: NT5DC2 on
chromosome 3; CCDC92, GPR109A, and ZNF664 on chromo-
some12; and PEPD on chromosome 19 (Table 3). The cis-eQTL
Table 1. Lead SNP per Locus for Genome-Wide Significant SNPs Arising from the Sex-Combined Meta-Analysis in European
Populations.
Nearest**
Gene Lead SNP{ Region Chr/position{ EA/NEA" EAF"" Beta1 SE P I2 n Beta1 SE P I2 n
Discovery Phase Results Joint Analysis Phase*
LYPLAL1 rs3001032 1q41 1/217794402 T/C 0.7 20.02 0.005 1.98E-06 0 29,321 20.02 0.004 3.60E-08 0 35,930
GNL3 rs1108842 3p21.1 3/52695120 C/A 0.50 0.03 0.004 3.66E-11 0.33 29,338 0.03 0.004 1.39E-13 0.2 35,962
TSC22D2 rs1597466 3q25.1 3/151538251 T/G 0.1 20.04 0.008 1.88E-08 0 29,319 20.03 0.007 1.62E-06 0.1 35,794
ADIPOQ rs6810075 3q27.3 3/188031259 T/C 0.6 0.06 0.005 3.60E-41 0 29,140 0.06 0.004 1.19E-43 0 35,749
VEGFA rs998584 6q21.1 6/43865874 C/A 0.5 0.03 0.005 5.84E-08 0.3 28,167 0.03 0.005 3.25E-08 0.2 34,108
TRIB1 rs2980879 8q24.13 8/126550657 T/A 0.7 0.03 0.005 1.08E-08 0 24,084 0.03 0.005 7.13E-09 0 30,708
PDE3A rs7955516 12q12.2 12/20389303 C/A 0.4 0.03 0.005 2.43E-08 0.1 29,178 0.02 0.004 4.45E-08 0 38,276
GPR109A rs601339 12q24.31 12/121740696 G/A 0.2 0.04 0.006 3.87E-11 0 29,325 0.03 0.005 7.81E-10 0.3 35,947
DNAH10 rs7133378 12q24.31 12/122975455 G/A 0.7 20.03 0.005 1.29E-09 0 29,223 20.02 0.004 6.21E-07 0.5 35,697
CMIP rs2925979 16q23.2 16/80092291 T/C 0.3 20.04 0.005 1.87E-18 0 29,347 20.04 0.005 1.21E-20 0 35,970
CDH13 rs12922394 16q23.3 16/81229828 T/C 0.1 20.10 0.011 3.16E-18 0.3 24,466 20.08 0.010 1.99E-15 0.4 31,089
PEPD rs731839 19q13.11 19/38590905 G/A 0.35 20.04 0.005 2.20E-13 0.03 29,166 20.03 0.004 7.97E-12 0.4 35,771
All SNPs achieving genome-wide significance in the joint analysis phase are marked in italics.
*Joint analysis indicates results from the meta-analysis of discovery and follow-up in-silico and de-novo phases.
**When possible, plausible biological candidate genes have been listed; otherwise, the closest gene is designated.
{Lead SNP is the SNP with the lowest p-value for each locus.
1Betas are estimated from models using the natural log transformed adiponectin.
"EA: Effect allele, NEA: Non-effect allele.
""EAF: Effect allele frequency.
doi:10.1371/journal.pgen.1002607.t001
Adiponectin: Multiethnic Genome-Wide Meta-Analysis
PLoS Genetics | www.plosgenetics.org 5 March 2012 | Volume 8 | Issue 3 | e1002607SNPs often are proxies for the lead SNPs from the GWAS,
however, this relationship may also be influenced through
mechanisms that are independent from gene expression, such as
gene function.
We next identified that mRNA levels of 18 genes arising from
six candidate loci were correlated with circulating adiponectin
levels (Table 4). Since circulating adiponectin levels may be
associated with a surplus of adipocyte transcripts we next tested
for enrichment of signal from the candidate loci. There were 133
transcripts in the identified candidate regions, of which 8.2% (11/
133) were associated with adiponectin levels at an array-wide
level of significance (p,2610
26), while 7.5% of the 24k probes
on the entire array exceeded the same p-value threshold,
indicating there was therefore no additional enrichment of signal
at these candidate loci.
T2D and Metabolic Traits
Using data from several large-scale GWAS consortia, some of the
significantly associated variants identified here demonstrated
associations with T2D and its related traits (Table S7A, S7B, S7C,
and S7D). Several individual SNPs showed evidence for association
with T2D and various metabolic traits after accounting for the
number of statistically independent SNPs (p-value threshold of
5610
24) among the SNPs that were genome-wide significant for
adiponectin. These include associations with HDL-C (n=104
SNPs), triglycerides (TG) (n=65 SNPs), total cholesterol (TC,
n=12 SNPs), LDL-cholesterol (LDL–C, n=11 SNPs), and waist-
hip ratio (WHR) (n=65 SNPs) [26]. (However, we note that since
sample sizes are different across different consortia power to identify
associations is not consistent.) Among these, coding and intronic
variants in STAB1 and NT5DC2 genes were associated with WHR
a n dH D L - C ,w h i l et h ev a r i a n t s1M bn e a rTRIB1 were associated
with all lipid traits. The coding and intronic variants ariants in the
locus on chromosome 12 harboring ZNF664, CCDC92,a n d
DNAH10 showed evidence of association with WHR, HDL-C, and
TG. Finally, variants in the PEPD gene were associated with TG.
We next calculated a multi-SNP genotypic risk score based
genome-wide significant SNPs from the discovery phase. This
multi-SNP genotypic risk score explained 5% of the variance of
natural log-transformed adiponectin levels. We then tested the
association of this risk score with risk of T2D and metabolic related
traits. The multi-SNP genotypic risk score was associated with
increased risk for T2D (ß=0.3, p=4.3610
23), where ß is the
average additive effect of adiponectin-decreasing risk alleles on the
Figure 1. Manhattan plots for meta-analyses in the discovery phase. A) Combined sex analysis in European populations, B) Meta-Analysis of
Multiple Ethnicities. The Manhattan plots show 2Log10 (p-value) measures for association between single nucleotide polymorphisms (SNPs) and
chromosomal position. The SNPs that achieved genome-wide significance are highlighted in green.
doi:10.1371/journal.pgen.1002607.g001
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PLoS Genetics | www.plosgenetics.org 6 March 2012 | Volume 8 | Issue 3 | e1002607Figure 2. Regional plots of eight newly discovered genome-wide significant chromosomal regions associated with adiponectin
concentrations in European populations. A) chromosome 16q23.2, B) chromosome 19 q13.11 C) Chromosome 3p21.1, D) two loci on
chromosome 12q24.31, E) chromosome 8q24.13, F) chromosome 6p21.1, and G) chromosome 1q41. In each panel, purple diamonds indicate the top
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214),
increased WHR adjusted for BMI (ß=0.18, p=1.8610
25),
increased post-prandial glucose (ß=0.25, p=0.01), increased
fasting insulin (ß=0.05, p=0.01), homeostatic model assessment-
insulin resistance (HOMA-IR) (ß=0.04, p=0.047), and with
lower HDL-C concentrations (ß=20.24, p=4.5610
213) and
decreased BMI (ß=20.16, p=1.4610
24). (Table 5).
Discussion
In this comprehensive multi-ethnic analysis of the genetic
influences on adiponectin levels and their impact on metabolic
traits and T2D, we have identified 10 novel loci and confirmed the
associations of variants in the ADIPOQ and CDH13 loci with
adiponectin levels. The adiponectin risk alleles were associated
with T2D and related metabolic traits such as BMI, WHR, TG,
HDL-C, 2-hour glucose, HOMA-IR and fasting insulin. These
findings demonstrate that adiponectin, T2D and metabolic
syndrome have a shared allelic architecture.
Biological Relevance of the GWAS Loci
In the first step toward understanding the biological relevance of
the identified regions, we examined the genes harbored by the
associated loci using human disease and animal databases.
Although some of the genes in these loci do not have a known
function, several signify diverse biological functions.
On chromosome 1, the lead SNP was located 300 kb from the
LYPLAL1, a protein that regulates phospholipids on cellular
membranes. Independent efforts have also identified this locus in
other metabolic/obesity related traits GWAS: first with WHR
(rs2605100;r
2=0.49 [21] and rs4846567;r
2=0.55[27] respectively
with the lead adiponectin SNP, rs3001032), and more recently with
fasting insulin by a joint meta-analysis including the interaction
between SNP and BMI (MF Hivert for the MAGIC investigators,
personal communication). In the same report by MAGIC, variants
near IRS1 (insulin receptor substrate 1) and PEPD (a protein that
hydrolyzes dipeptides and tripeptides) have also been associated
with fasting insulin at genome wide significant levels, demonstrating
a close link between adiponectin regulation and insulin resistance
pathways. Moreover, both IRS1 and PEPD have been associated
with T2D (IRS1 in DIAGRAM [28] and PEPD in a Japanese
population [29]; p=9.3610
212 and p=1.4610
25, respectively).
The lead SNP at 3p21.1 falls within GNL3 that is located in a
genomic region containing many genes which could have potential
functions in metabolism. Our data provide evidence that
adiponectin levels were correlated with human adipocyte mRNA
levels of many genes in this region (GLYCTK, SEMA3G, STAB1,
PBRM1, SFMBT1; see Table 4). However, this association does
not imply a direct influence of these genes on adiponectin level.
Among those genes, STAB1 encodes for stabilin 1, described as an
endocytic receptor for advanced glycation end products and may
have a function in angiogenesis, lymphocyte homing, cell
adhesion, or receptor scavenging for acetylated low-density
lipoprotein [30].
Interestingly, several of the genes near lead genome-wide
significant SNPs have been implicated in angiogenesis, which
might be important for adipose tissue expansion, highlighting the
recurring theme of ‘‘adipose tissue expandability’’ in the genetic
origins of obesity-related complications [31]. For example, VEGFA
is the vascular endothelial growth factor A gene, a known gene in a
variety of vascular endothelial cell functions, such as angiogenesis
and maintenance of the glomerular endothelium in nephrons [32].
Variants in this gene are also associated with diabetic retinopathy
and WHR [27,33]. Moreover, the product of VEGFA interacts
with resveratrol, which has been shown to have a beneficial
influence in some metabolic traits, including diabetes [34]. Rodent
studies show that resveratrol decreases blood glucose, blood
insulin, and glycated hemoglobin, as well as increases insulin
sensitivity in animals with hyperglycemia (reviewed in [35]).
Resveratrol also inhibits TNF-a-induced reductions in adiponectin
levels in 3T3-L1 adipocytes [36]. Furthermore, it has been shown
that resveratrol modulates adiponectin expression and improves
insulin sensitivity, likely through the inhibition of inflammatory-
like response in adipocytes [37]. At this locus, VEGFA mRNA
levels in adipocytes were the strongest association with adiponectin
levels (Table 4). Also likely involved in vascular biology, TRIB1
encodes a G protein-coupled receptor-induced protein interacting
with MAP kinases that regulates proliferation and chemotaxis of
vascular smooth muscle cells [38]. TRIB1 expression was shown to
be elevated in human atherosclerotic arteries [39]. Several variants
(rs2954029, rs2954021, rs17321515; all in moderate LD with our
lead SNP) in the TRIB1 gene have been associated with HDL-C,
LDL-C and CHD risk in European and Asian populations
[22,40,41,42,43]. These two loci (TRIB1 and VEGFA) argue for
the importance of vascular biology in adiponectin regulation as
underlined previously by findings of adiponectin levels associated
with variants near CDH13 (a receptor for adiponectin expressed by
endothelial smooth muscle) [44].
All three homologous genes GPR109A/B/81 located on
chromosome 12 are predominantly expressed in adipocytes and
mediate antilipolytic effects [45]. Our eQTL results (Table 3) and
the correlation between mRNA and adiponectin levels (Table 4)
argue strongly for a role of GPR109A at this locus. GPR109A (also
known as NIACR1) is a receptor with a high-affinity, concentra-
tion-dependent response to nicotinic acid (niacin) [45]. Treatment
by niacin increases serum adiponectin levels by up to 94% in obese
men with metabolic syndrome in a time- and dose-dependent
manner [46]. Functional studies in GPR109A receptor knockout
mice demonstrate that niacin increases serum total and HMW
adiponectin concentrations and decreases lipolysis following
GPR109A receptor activation [47]. Moreover, a recent meta-
analysis on cohorts containing extremes of HDL-C provided
evidence suggestive of association in GPR109A/B/81 [48].
Finally, variants in ZNF664 have been associated with CHD,
HDL-C and TG levels in a large meta-analysis of over 100,000
individuals of European ancestry [22]. The sex heterogeneity
observed in this study is comparable to our finding that the more
loci associated with adiponectin at genome wide significance level
have been shown in female stratified analysis.
Taken together, the loci identified in this large-scale GWAS for
adiponectin levels highlight many genes with demonstrated
relationships with metabolic disease.
Shared Allelic Architecture of Adiponectin Levels and
Metabolic Traits
Using a multi-SNP genotypic risk score we attempted to
understand if the allelic architecture of adiponectin levels was
shared with T2D and metabolic traits. This risk score was
SNPs, which have the strongest evidence of association. Each circle shows a SNP with a color scale relating the r
2 value for that SNP and the top SNP
from HapMap CEU. Blue lines indicate estimated recombination rates from HapMap. The bottom panels illustrate the relative position of genes near
each locus. Candidate genes are indicated by red ovals.
doi:10.1371/journal.pgen.1002607.g002
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PLoS Genetics | www.plosgenetics.org 9 March 2012 | Volume 8 | Issue 3 | e1002607associated with increased risk of T2D and traits associated with
insulin resistance and the metabolic syndrome. However,
unexpectedly, adiponectin decreasing alleles were associated with
a decrease in BMI. In our adiponectin GWAS, BMI was included
as a covariate in order to avoid direct identification of obesity
SNPs since BMI is strongly related to adiponectin levels [49,50].
Furthermore, this unexpected direction of effect was entirely
explained by SNPs at the ZNF664 and PEPD loci; when these loci
were removed from the analysis, the association of the genotypic
risk score with BMI disappeared (results not shown). Therefore,
adiponectin risk alleles at ZNF664 and PEPD are of considerable
interest since they impart deleterious changes on aspects of the
metabolic syndrome (increased TC, TG, LDL-C and WHR and
decreased HDL-C), but also act to decrease BMI and percent fat.
Our data do not provide direct evidence as to whether the
genetic determinants of adiponectin levels influence these traits
through adiponectin itself, or through pleiotropic pathways and
therefore do not constitute a Mendelian randomization study.
These findings provide a note of caution for Mendelian
randomization studies, which may be prone to erroneous
conclusions if pleiotropic effects of tested variants are not
considered. Nonetheless, in aggregate, these results provide strong
evidence that the genetic determinants of adiponectin levels are
shared with metabolic disease, and in particular, traits related to
insulin resistance.
We note that there are several strengths and limitations of this
study. Our main findings, identifying genetic determinants of
adiponectin levels, are based on the largest meta-analysis to date
and include results from three ethnicities. The availability of
expression data from human adipose tissue permitted the
association of identified SNPs with mRNA levels at candidate
genes and, in turn, correlation of these mRNA levels with
circulating adiponectin itself. While access to the data from large
consortia permitted assessment of the relevance of the identified
SNPs to T2D and components of the metabolic syndrome, we
note that a subset of the cohorts included in our GWAS were also
included in these external consortia. However, we note that even if
we assume that all ADIPOGen study participants were included in
the external consortia, for cohorts participating in both studies,
that the majority of data in these external consortia still arises from
study participants not present in ADIPOGen (minimum percent of
non-overlapping subects: 86.8%, 85.5%, 86.4% and 82.5% for
MAGIC, GLGC, GIANT, and DIAGRAM+ consortia, respec-
tively). Therefore, since a substantial majority of participants are
independent between ADIPOGen and these consortia, it is
unlikely that our findings demonstrating a shared allelic architec-
ture between adiponectin levels and these traits are spurious.
Further, we suggest that locus, 6q24.1, identified only through
multi-ethnic meta-analysis using MANTRA and not confirmed
through fixed and random effects meta-analysis, be replicated for
confirmation of this finding.
In conclusion, the data presented in this study provide strong
evidence of association for 10 novel loci for adiponectin levels.
Table 3. The Association of Lead Genome-Wide Significant SNPs for Adiponectin with mRNA Levels of Their Nearest Gene.
Gene
Lead SNP-
Cis-eQTL{ Chr
Transcript
Start Site
Transcript
End Site EA" EAF"" Beta (SE)1 P-Exp* P-GWAS**
lead SNP-
GWAS{{ r
2$
NT5DC2 rs13081028 3 52533424 52544133 G 0.444 0.14(0.02) 1.32E-19 1.05E-09 rs1108842 0.84
GPR109A rs2454722* 12 121778105 121781082 G 0.166 20.15(0.03) 1.71E-09 3.87E-11 rs601339 1
CCDC92 rs10773049 12 122986907 123023116 T 0.611 0.15(0.02) 8.09E-22 2.67E-08 rs7133378 0.02
ZNF664 rs825453 12 123074711 123065922 T 0.615 20.04(0.01) 4.51E-05 4.03E-08 rs7978610 0.03
PEPD rs8182584 19 38569694 38704639 T 0.364 20.13(0.02) 9.96E-10 6.64E-11 rs731839 1
{Lead SNP is the SNP with the lowest p-value for each gene in gene expression data.
{{Lead SNP is the SNP with the lowest p-value for each locus in meta-analysis from discovery phase.
"EA: Effect allele.
""EAF: Frequency of effect allele.
1Betas are estimated expression levels of the genes.
*P value for lead SNP is the SNP in gene expression data.
**P value for lead SNP in meta-analysis from discovery phase.
$r
2 LD between lead SNP from expression and lead SNP from meta-analysis.
doi:10.1371/journal.pgen.1002607.t003
Table 4. The Association of mRNA Levels from Genes in
Candidate Loci in Human Adipocytes with Circulating
Adiponectin Levels.
Gene Gene region GeneStart GeneEnd Beta1 Pvalue
GLYCTK 3p21.1 52296875 52304311 0.060 1.77E-20
SEMA3G 3p21.1 52442307 52454083 20.018 9.28E-06
STAB1 3p21.1 52504395 52533551 20.039 2.26E-14
PBRM1 3p21.1 52554407 52688779 0.007 2.49E-04
SFMBT1 3p21.1 52913666 53055110 0.010 2.53E-08
DNAJB11 3q27.3 187771160 187786283 20.014 3.31E-07
EIF4A2 3q27.3 187984054 187990379 0.021 1.53E-08
ADIPOQ 3q27.3 188043156 188058944 0.054 1.03E-13
MAD2L1BP 6q21.1 43711554 43716666 0.009 4.09E-04
VEGFA 6q21.1 43845923 43862199 0.012 2.15E-09
ZCCHC8 12q24.31* 121523387 121551471 0.011 2.60E-04
GPR109B 12q24.31 121765255 121767392 0.010 3.74E-06
GPR109A 12q24.31 121778105 121781082 0.026 1.80E-11
PITPNM2 12q24.31* 122033979 122160928 20.010 5.09E-06
U1SNRNPBP 12q24.31 122508604 122516894 0.011 1.72E-04
ATP6V0A2 12q24.31 122762817 122812252 20.008 2.86E-04
ZNF664 12q24.31 123023622 123065922 0.010 8.28E-06
SLC7A10 19q13.11 38391409 38408596 0.072 1.66E-14
1Betas are estimated from log transformed and quantile-quantile normalized
values.
*These two loci are independent loci.
doi:10.1371/journal.pgen.1002607.t004
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PLoS Genetics | www.plosgenetics.org 10 March 2012 | Volume 8 | Issue 3 | e1002607Further analyses confirmed that the level of expression of some of
these candidate genes in human adipocytes correlated directly with
adiponectin levels. A multi-SNP genotypic risk score, and several
of the identified variants, directly influence parameters of the
metabolic syndrome and, in particular, markers of insulin
resistance. These findings identify novel genetic determinants of
adiponectin levels, which, taken together, influence risk of T2D
and markers of insulin resistance.
Materials and Methods
Ethical Consideration
All participants provided informed written consent. The
research protocol of all studies were reviewed and approved by
institutional ethics review committees at the involved institutions.
Study Design
Our study consisted of three stages. First, in the discovery stage
we performed a meta-analysis of the GWAS summary statistics of
16 studies involving 29,347 participants of white European origin
to detect SNPs that are associated with adiponectin levels. All
signals with p,5610
26 were followed up in seven additional
cohorts (n=6,623) with GWAS data (in-silico phase) that later
joined the consortium and then a subset of SNPs (n=10) by de-novo
genotyping in 3,913 additional participants from three cohorts
(n=39,883 for the combined analysis in Europeans). We also
performed a multi-ethnic meta-analysis by combining summary
statistics from the 16 studies of individuals of white European
discovery cohorts (n=29,347) with those of five cohort studies that
included African Americans subjects (n=4,232) and one East
Asian cohort (n=1,776) to obtain a total 35,355 individuals for the
GWAS meta-analysis involving different ethnicities. After identi-
fying variation near two genes of pharmaceutical importance
(GPR109A and GPR109B), which encode the putative niacin
receptors, we typed additional rare coding and tagging variants in
a subset of cohorts. Second, we examined whether the identified
SNPs of the first stage also associate with mRNA levels of nearest
gene(s) expressed using adipose tissue of 776 European women.
We also tested for association between adiponectin levels and
mRNA levels of the genes in our candidate loci in adipose tissue of
a subgroup of 436 individuals [25]. Third, we calculated a multi-
SNP genotypic risk score using genome-wide significant adipo-
nectin-lowering alleles and tested the association of this risk score
with T2D and related metabolic traits. Figure 3 shows a flow chart
detailing the study design.
Study Populations
In total, 45,891 individuals from 26 European and 7 non-
European cohorts participated in the different phases of this meta-
analysis. Participating cohorts were either population-based
(n=23), family-based (n=4), or case-control (n=4) studies. The
age of participants ranged from 10 to 95 years. Adiponectin levels
were measured using ELISA or RIA methods. More details on the
study cohorts and adiponectin measurement are presented in the
Text S1 and Table S1. In addition, genotyping of four coding and
tagging SNPs in the candidate genes, GRP109A and GPR109B,
was undertaken in samples from the Lausanne, Lolipop, MRC
Ely, and Fenland cohorts.
Genotyping and Imputation
All cohorts were genotyped using commercially available
Affymetrix or Illumina genome-wide genotyping arrays. Quality
control was performed for each study independently and genotype
imputation was carried out using IMPUTE, MACH, BimBam or
Beagle with reference to either the Phase II CEU, CEU+YRI, or
CHB+JPT+CEU HapMap according to the origin of population.
Imputation of East Asian genotypes was undertaken by first
masking genotypes of 200 SNPs and then imputing them based on
the CEU+CHB+JPT panel from HapMap. This resulted in an
allelic concordance rate of ,96.7%. For the African Americans, a
combined CEU+YRI reference panel was created. This panel
included SNPs segregating in both CEU and YRI, as well as SNPs
Table 5. Results of Association of Multi-SNP Genotypic Risk Score with Diabetes and Related Traits.
Trait N Effect1 (95% CI) P Consortium
T2D** 22,044 0.301 (0.09, 0.51) 4.3E-03 DIAGRAM+
BMI (SD units) 121,335 20.162 (20.25, 20.08) 1.4E-04 GIANT
WHR* 77,167 0.177 (0.1, 0.26) 1.8E-05 GIANT
Percent Fat 34,853 20.052 (20.15, 0.05) 0.31 Body Fat Percent
Fasting Glucose (mmol/L) 46,186 0.011 (20.03, 0.05) 0.58 MAGIC
Fasting Insulin**(pmol/L) 38,238 0.05 (0.01, 0.09) 1.5E-02 MAGIC
HomaB 36,466 0.033 (0, 0.07) 5.1E-02 MAGIC
Homa IR 37,037 0.042 (0, 0.08) 4.7E-02 MAGIC
2hr Glucose**(mmol/L) 15,234 0.245 (0.06, 0.44) 1.1E-02 MAGIC
HbA1C (%) 35,908 20.002 (20.04, 0.03) 0.91 MAGIC
TG**(SD units) 93,440 0.248 (0.18, 0.31) 2.6E-14 GLGC
HDL-C** (SD units) 96,748 20.243 (20.31, 20.18) 4.5E-13 GLGC
LDL-C (SD units) 92,348 0.023 (20.05, 0.09) 0.52 GLGC
TC (SD units) 97,021 0.0003 (20.07, 0.07) 0.99 GLGC
T2D: Type 2 diabetes, BMI: Body mass Index, WHR: Waist to hip ratio, HbA1C: hemoglobin A1C, TG: Triglyceride, HDL-C: High Density Lipoprotein Cholesterol, LDL-C:
Low Density Lipoprotein Cholesterol, TC: Total Cholesterol.
1Effect is mean change in trait or disease per adiponectin-decreasing allele.
*Waist to hip ratio adjusted for BMI.
**Significantly associated trait is coded in bold.
doi:10.1371/journal.pgen.1002607.t005
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the other (2.74 million SNPs). Due to the overlap of African
American individuals on the Affymetrix 6.0 and IBC arrays [51], it
was possible to analyze imputation performance at SNPs not
genotyped on Affymetrix 6.0. For imputation based on Affymetrix
data, the use of the CEU+YRI panel resulted in an allelic
concordance rate of ,95.6% (calculated as 120.5 * [imputed_
dosage– chip_dosage]). This rate is comparable to rates calculated
for individuals of African descent imputed with the HapMap 2
YRI individuals. Table S1 summarizes the genotyping methods
used for each cohort, genotype-calling algorithms, imputation
algorithms and exclusion thresholds. SNP-level quality control
metrics were applied prior to meta-analysis for each cohort. These
were: call rate $95%, minor allele frequency (MAF)$1%, Hardy-
Weinberg equilibrium (HWE) p.10
26, and quality measures for
imputed SNPs (r
2$0.3, or proper info $0.4, for cohorts imputing
their data with MACH and IMPUTE, respectively).
Eleven coding and tagging variants in two candidate genes of
pharmaceutical importance (GPR109A encoding the niacin
receptor and GPR109B) were genotyped in a parallel study in
Lausanne, Lolipop, MRC Ely, and Fenland white subjects.
Genotyping was performed using a KASPar-On-Demand SNP
Genotyping Assay (KBioscience Ltd., Hoddesdon, UK). In
Lausanne and Lolipop samples the genotyping assay was carried
out on 3.75 ng of genomic DNA in 1 ml 1536-well plate reactions,
dispensed with a Meridian, microfluidic dispenser (KBioscience
Ltd., Hoddesdon, UK), thermocycled using a Hydrocycler
(KBioscience Ltd., Hoddesdon, UK). A Pherastar (BMG GmbH,
Germany) was used for end-point detection and Kraken-LIMS
(KBioscience Ltd., Hoddesdon, UK) was used for automated allele
calling. In MRC Ely and Fenland samples, the genotyping assay
was carried out on 10 ng of genomic DNA in 5 ml 384-well plate
reactions using a G-Storm GS4 Thermal Cycler (GRI, Rayne,
UK). The ABI PRISM 7900HT Sequence Detection System
(Applied Biosystems, Warrington, UK) was used for end-point
detection and allele calling.
Statistical Analysis
Genome-wide association studies. All cohorts indepen-
dently tested for the additive genetic association of common
(MAF.1%) genotyped and imputed SNPs with natural log
transformed adiponectin levels, while adjusting for age, sex,
body mass index (BMI), principal components of population
stratification and study site (where appropriate), and for family
structure in cohorts with family members [49,50,52]. The analyses
were performed for men and women combined, as well as for men
and women separately. The Cardiovascular Health Study cohort
(CHS) also provided GWA results for high molecular weight
(HMW) adiponectin using the same methods as described above.
Meta-analysis of GWAS. The meta-analysis was performed
by two analysts independently each using different methods;
inverse variance-weighted methods using both fixed and random
effect models available through either the METAL (http://www.
sph.umich.edu/csg/abecasis/metal/) or GWAMA version 2.0.5
(http://www.well.ox.ac.uk/gwama/) software packages [53].
Summary statistics were crosschecked to ensure consistency of
results. Prior to the meta-analysis, study-specific summary statistics
were corrected using genomic control (lambda range=0.99–1.25)
and the overall meta-analytic results were additionally corrected
for genomic control (lambda=1.06). To examine whether
associations with adiponectin were sex-specific, we performed
meta-analyses for men and women separately. A p-value threshold
of 5610
28 was considered to be genome-wide significant.
Ethnicity-specific meta-analyses were performed for white Euro-
pean and non-European populations separately, using the same
methods as described above.
Presence of heterogeneity in the meta-analysis was assessed by
the I
2 statistic and Q-test [54]. Since cohorts measured
adiponectin concentrations using either RIA or ELISA methods,
we also performed a GWA meta-analysis stratified by the method
of measurement to test whether this contributed to heterogeneity.
Follow-up phase. The follow-up phase comprised two stages;
in-silico follow-up and de-novo follow-up.
—In silico follow-up: 468 SNPs with p,5610
26 from the
discovery phase (which includes both genome-wide significant
[n=196, p,5610
28] and ‘‘suggestive’’ [n=272, 5610
28,p,
5610
26] SNPs Table S3) were tested for their association in 6,623
individuals from seven additional cohorts with GWAS data that
joined the consortium after the discovery stage had been finalized.
—De novo follow-up: We next selected the lead SNP arising
from selected loci from the joint analysis of the discovery and in-
silico follow-up phase with p-values greater than 5610
28 but less
than 5610
26 and genotyped 10 SNPs in 3,164 samples from the
SAPHIR cohort and an additional subgroup of the KORA cohort.
Finally, these same SNPs, or their proxy SNPs (n=2), were tested
for association in the THISEAS cohort (n=738), which had been
genotyped using the Metabochip [55]. Study-level summary
statistics from the follow-up phases were meta-analyzed with the
data from the discovery phase.
Multi-ethnic meta-analysis. In order to perform a meta-
analysis of GWAS data from cohorts of different ethnic
backgrounds, we utilized the novel MANTRA (Meta-ANalysis of
Trans-ethnic Association studies) software [24]. This method
combines GWAS from different ethnic groups by taking
advantage of the expected similarity in allelic effects between the
most closely related populations. Fixed-effects meta-analysis
assumes the allelic effect to be the same in all populations, and
cannot account for heterogeneity between ethnic groups.
Conversely, random effects meta-analysis assumes that each
population has a different underlying allelic effect, however,
populations from the same ethnic group would be more
homogeneous than those that are more distantly related. To
address this challenge we accounted for the expected similarity in
allelic effects between the most closely related populations by means
of a Bayesian partition model. For each variant, allelic effects and
correspondingstandard errors are estimated withineachpopulation
under the assumption of an additive model. Populations are then
clustered according to their similarity in terms of relatedness as
measured by the mean allele frequency difference at 10,000
independent SNPs, and to their allelic effects at the variant. If all
populations are assigned to the same cluster, this is equivalent to a
fixed allelic effect across all populations (i.e. no trans-ethnic
heterogeneity). The posterior distribution of the allelic effect in
each population under the Bayesian partition model is
approximated by means of a Monte-Carlo Markov chain
algorithm. Evidence in favor of association of the trait with the
variant was assessed by means of a Bayes’ factor (BF). A log10 BF of
6 or higher is considered a relatively conservative threshold for
genome-wide significance. We also performed meta-analysis by
using both random and fixed effects models including all ethnicities.
Those loci that achieved both a BF.6 in MANTRA and a P-value
less than 5610
27 in multiethnic analysis are presented in Table 2.
Association of Genome-Wide Significant SNPs with Gene
Expression (Stage 2)
In order to identify cis-expression quantitative trait loci (cis-
eQTLs) and test whether mRNA levels of candidate genes arising
from our GWAS were associated with adiponectin levels, we used
Adiponectin: Multiethnic Genome-Wide Meta-Analysis
PLoS Genetics | www.plosgenetics.org 12 March 2012 | Volume 8 | Issue 3 | e1002607expression profiles in human adipocytes from the Multiple Tissue
Human Expression Resource (MuTHER) Consortium, (856
female twins from the UK) [25]. mRNA expression profiles from
subcutaneous fat and genome-wide genotypes were available for
776 individuals and circulating adiponectin levels for 436 of these
women. We note that while adiponectin levels were measured at
an earlier time point than the fat biopsies, the BMI at time of
adipose expression measurement and time of adiponectin
measurement was highly correlated (r
2=0.9).
cis-eQTLs were defined as associations between SNPs and a
transcript within 1 Mb of the identified SNP. To correct for
multiple testing, we used QVALUE software [56], and estimated
that a genome-wide false discovery rate of 1% corresponds to a p-
value threshold of 5.06610
25 (this conservative threshold accounts
forallmultiplearisingfromthe use ofthearray,ratherthanmultiple
testing arising from assessing only transcripts in the genome-wide
significant regions). To test whether mRNA levels of candidate
genes identified in the GWAS meta-analysis are associated with
circulating adiponectin levels, we applied a Bonferoni corrected
threshold of p,3610
24 (where 3610
24=0.05/133 and 133 was
the number of transcripts tested at the candidate loci).
Association of Genome-Wide Significant SNPs with T2D
and Metabolic Traits (Stage 3)
The DIAGRAM+ (effective n=22,044) [19], MAGIC (n=up
to 46,186) [20], GLGC (n=up to 97,021) [22], GIANT (n=up to
121,335) [21], and Body Fat GWAS (n=up to 36,625) consortia
provided summary statistics for the association of each SNP that
was genome-wide significant in the discovery phase. Since 196
SNPs (which were estimated to be equivalent to 96 independent
statistical tests due to linkage disequilibrium [LD]) [26] were tested
for their association, we employed a Bonferroni-corrected
threshold of a=0.0005 (where 0.0005=0.05/96) to define the
threshold of association for any individual SNP association with
T2D and related traits.
While any individual SNP may demonstrate a relationship with
T2D or related traits, it can be more informative to test whether a
multi-SNP genotypic risk score is associated with the outcome of
interest. In the absence of pleiotropic effects arising from loci other
than ADIPOQ, such a multi-SNP genotypic risk score would enable
testing of whether adiponectin levels are causally related to risk of
T2D or metabolic traits through a Mendelian randomization
framework. Since most of the SNPs that we identified to be
genome-wide significant for adiponectin levels were not in the
ADIPOQ locus, the presence of such pleiotropy precluded a formal
Mendelian randomization study. To create a multi-SNP genotypic
risk score we implemented a novel method that approximates the
average effect of adiponectin decreasing alleles on T2D or related
traits. Further, this method allows the use of consortium-level
meta-analytic results for a set of SNPs, rather than requiring the
re-analysis of individual-level data in each cohort, thereby
providing more accurate effects of each allele (due to the larger
sample size in the consortium-level meta-analysis). The weighted
sum of the individual SNP coefficients leads not only to an
estimate of the average combined allelic effect, but also to an
approximate estimate of the explained variance (when scaled by
the inverse of the total meta-analysis sample size) from a
multivariate regression model containing these SNPs.
Figure 3. Flow chart of study design.
doi:10.1371/journal.pgen.1002607.g003
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PLoS Genetics | www.plosgenetics.org 13 March 2012 | Volume 8 | Issue 3 | e1002607Specifically, suppose m SNPs have shown association in the
discovery phase, and effects are denoted wi. However, suppose that
the goal of interest is to estimate the joint effect of these SNPs on
an outcome of interest, y. Let j index the individuals in the
outcome of interest dataset and let
sj~
Xm
i~1 wixij
be a risk score based on the discovery data SNPs, and their
associated parameter estimates wi. Therefore, the desired goal is
to estimate the parameter in the following equation:
yj~y0zasjzej in the outcome of interest dataset. The
proportion of variance in y explained by the previous equation,
(i.e. the R
2) attributable to the risk score can be estimated.
Standard linear model theory shows that the change in log
likelihood is proportional to the R
2,
2½lnL(M1){lnL(M0) %nR2
If the SNPs are uncorrelated, and if the total percentage of
variance explained is small, then the change in log likelihood can
be approximated by
C{
X m
i~1
bi{^ b bi
   2
2s2
i
where bi now refers to the effect of SNP i in the outcome data, ^ b bi
is the outcome data estimate, and si is the associated standard
error estimate. Assuming that this log likelihood difference
approximation is maximized with an appropriate value of C,
then it can be shown that a can be estimated by:
^ a a%
Pm
i~1 wi^ b bisi
{2
Pm
i~1 w2
i s{2
i
with a standard error estimate of
se(^ a a)%
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
Pm
i~1 w2
i s{2
i
s
Therefore, under the assumption of uncorrelated SNPs, their
joint effect can be estimated in external data by a weighted mean
of the individual SNP effects, weighted by the estimates from the
discovery data. All these quantities can be obtained from meta-
analysis or summary data, so that individual-level data are not
required to obtain these results.
To implement this method, we first selected LD-independent
adiponectin associated alleles by LD pruning the set of genome-
wide significant adiponectin SNPs from the discovery phase with
an LD threshold of r
2#0.05 in the HapMap CEU population,
yielding 20 independent LD blocks from the 196 SNPs in Table
S2. (We also applied the method using an LD threshold of
r
2#0.01 and found no relevant change in results). Since many
SNPs from the same independent blocks were associated with
adiponectin, we selected the SNP from the LD block that
explained the most variance in adiponectin levels. Next, we
approximated the effect of the multi-SNP genetic risk score using
b and its standard error as derived from the consortium-level
meta-analysis in DIAGRAM+, MAGIC, GLGC, GIANT and
Body Fat GWAS consortium.
Supporting Information
Figure S1 The comparison between two independent meta-
analyses performed in different centers for quality control
purposes. The 2log10 p-value of all SNPS with MAF$0.01 in
the first analysis are plotted against the 2log10 p-value from the
second analysis.
(TIF)
Figure S2 The Manhattan plots of sex-stratified meta-analyses
in the discovery phase in the European population. The meta-
analysis shown in panel a) is stratified for women and that in panel
b) is stratified for men. Manhattan plots demonstrate 2Log 10(p-
value) measures for association between single nucleotide poly-
morphisms (SNPs) and chromosomal position. The SNPs that
achieved genome-wide significance are highlighted in green in the
plots. The red ovals identify loci found only in women.
(TIF)
Figure S3 Association Results Near Peaks for Sex-specific
Analysis of Adiponectin. SNPs in regions near peak associations
are shown for a) chromosome 8 female, b) chromosome 8 males, c)
chromosome 12 females and d) chromosome 12 males. Purple
diamonds indicate the top SNPs, which have the strongest
evidence of association in women. Each circle shows a SNP with
a color scale proportional to the r
2 value for that SNP and the top
SNP from HapMap CEU. Blue lines show the estimated
recombination rates from HapMap. The bottom panels illustrate
the relative position of each gene in the locus.
(TIF)
Table S1 Cohort characteristics.
(XLSX)
Table S2 Comparing the Genome-Wide Significant SNPS from
fixed effect model with random effect model. *SNP with I
2 less
than 0.5 are listed in bold, EA: Effect Allele, NEA: Non-Effect
Allele.
(PDF)
Table S3 Association Results of SNPs achieving p#5610
26 in
the Discovery phase in European Populations (Sex-Combined
Analysis). *Denotes SNPs typed in the de-novo follow-up phase.
(PDF)
Table S4 Genome-Wide Significant SNPs (p,5610
28) Associ-
ated with Adiponectin Levels in Non-Europeans Populations. EA:
Effect Allele, NEA: Non-Effect Allele, EA-Freq: Frequency of
Effect Allele.
(PDF)
Table S5 SNPs associated with adiponectin at genome-wide
significant levels (p,5610
28) using the fixed-effect model in
women only in European populations (including Discovery and
Follow-Up phases).
(PDF)
Table S6 SNPs associated with adiponectin at genome-wide
significant levels (p,5610
28) using fixed-effect models in men
only in Euopean populations.
(PDF)
Table S7 Association results of nominally significant SNPs with
Type 2 Diabetes in the DIAGRAM+ Consortium. EA: Effect
Allele, NEA: Non-Effect Allele. B) Association results of nominally
significant SNPs with diabetes-related traits in the MAGIC
Consortium. Fasting glucose and 2 h glucose in mmol/L; Insulin
in pmol/L, EA: Effect Allele, NEA: Non-Effect Allele. C)
Association results of nominally significant SNPs with diabetes-
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PLoS Genetics | www.plosgenetics.org 14 March 2012 | Volume 8 | Issue 3 | e1002607related traits in the GIANT and Body fat GWAS consortia. The
beta expressed in inverse normally transformed BMI units (i.e.
interpretable as SD or Z-score), shows the change in BMI per
additional effect allele.,*Results that are statistically significant,
accounting for the number of independent SNPs, are highlighted
in bold., EA: Effect Allele, NEA: Non-Effect Allele, EA-Freq:
Frequency of Effect Allele. D) Association results of nominally
significant SNPs with lipid traits in the GLGC Consortium. For
these traits the effect size is in SD units, based on standard error-
weighted meta-analysis. *Results that are statistically significant,
accounting for the number of independent SNPs are highlighted in
bold., EA: Effect Allele, NEA: Non-Effect Allele, EA-Freq:
Frequency of Effect Allele.
(PDF)
Text S1 Supplemental data include description of study cohorts
and funding.
(DOCX)
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